2025 has been an important year for mAbsolve. We are pleased to report that two of our commercial licensees have now entered clinical trials using our STR technology. These are significant milestones for the company. Published clinical data from STR-based products has long been the key missing piece needed to accelerate broader adoption of our … Read more
With the grant of additional patents in the USA (US1249744) and Japan (JP7791867), mAbsolve’s patent coverage has been further extended to include nucleic acids and Fc fusion proteins which incorporate the STR technology. These divisional patents build on our existing granted patents in the United States, Japan, United Kingdom, Canada and Australia, which cover antibodies … Read more
Today mAbsolve along with collaborators at RIC and Protein Stable, published a peer-reviewed article analysing over 70 different Fc silencing variants that have been reported in the literature. This by far the most comprehensive analysis of silencing variants ever reported. mAbsolve’s STR mutations are included in this report and are identified as superior based on … Read more
The Nonhuman Primate Reagent Resource (NHPRR), part of the University of Massachusetts Medical School, and mAbsolve, developers of a novel Fc silencing variant, today announced a licensing deal for mAbsolve’s Fc silencing technology. The full press release is available in the PDF below.
mAbsolve CEO has today published a review on the history of antibody Fc silencing. This covers Geoff’s personal experiences and insights with silencing over his career. A must read for anybody interested in Fc silencing and therapeutic antibody history in general.
mAbsolve has now had patents for the STR silencing mutations granted in the United States (US12037380B2), Canada (CA3179582), United Kingdom (GB2595299B), Australia (AU2021277578B2) and Japan (JP7434609B2). We continue to push forward with our applications in other territories and expect these to be awarded in due course.
Antibody Solutions have licensed our STR technology to provide their clients with access to this cutting edge technology during their discovery campaigns. See the full press release below for more details.
mAbsolve will be exhibiting at the Festival of Biologics in Basel on the 10-12th of October. We will be located in the startup zone will also have a poster with a more detailed description of our technology in the poster area. Please do come along and chat with us to understand how we can help … Read more
The Medical and Healthcare products Regulatory Agency (MHRA) has licensed mAbsolves novel Fc silencing technology to produce gold standard negative controls for Fc receptor binding assays. The full press release is below.
OmniAb have entered into a licensing agreement for STR. The agreement provides OmniAb with exclusive, sublicensable access to the STR technology for antibodies that have been generated using OmniAb’s antibody discovery platform. For the full press release please see the PDF below.